Search
enVVeno Medical Corp
NVNOAdd to Watchlist
11.110USD
+0.310+2.80%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.29MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.80%
5 Days
+2.49%
1 Month
+3.35%
6 Months
-9.31%
Year to Date
-1.05%
1 Year
+178.45%
Key Figures
10.757Open
11.250High
4.85KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.74%Turnover Ratio
10.830Prev. Close
10.757Low
43.86KTurnover
LossP/E Static
0.31P/B
0.00%Div Yield TTM
-56.45%ROA
196.70052wk High
1.48Volume Ratio
-21.82MNet Profit
656.00KShares
-1155.2209EPS TTM
1.09Beta
-60.65%ROE
8.67052wk Low
4.55%Amplitude
--Gross Margin
7.29MMarket Cap
0.13Reward/Risk
5.63%Risk Rate
TradingKey Stock Score of enVVeno Medical Corp
Currency: USD Updated: 2026-07-02Key Insights
enVVeno Medical Corp's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 215 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 12.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
enVVeno Medical Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
enVVeno Medical Corp Highlights
StrengthsRisks
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Overvalued
The company’s latest PE is -0.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 184.36K shares, decreasing 34.20% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
12.500
Target Price
+1517.29%
Upside Space
enVVeno Medical Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
enVVeno Medical Corp Info
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Ticker SymbolNVNO
CompanyenVVeno Medical Corp
CEOBerman (Robert A)
Websitehttps://envveno.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of enVVeno Medical Corp (NVNO)?
The current price of enVVeno Medical Corp (NVNO) is 11.11.
What is the symbol of enVVeno Medical Corp?
The ticker symbol of enVVeno Medical Corp is NVNO.
What is the 52-week high of enVVeno Medical Corp?
The 52-week high of enVVeno Medical Corp is 196.70.
What is the 52-week low of enVVeno Medical Corp?
The 52-week low of enVVeno Medical Corp is 8.67.
What is the market capitalization of enVVeno Medical Corp?
The market capitalization of enVVeno Medical Corp is 7.29M.
Is enVVeno Medical Corp (NVNO) currently rated as Buy, Hold, or Sell?
According to analysts, enVVeno Medical Corp (NVNO) has an overall rating of signal_hold, with a price target of 12.50.
What is the Earnings Per Share (EPS TTM) of enVVeno Medical Corp (NVNO)?
The Earnings Per Share (EPS TTM) of enVVeno Medical Corp (NVNO) is -1157.08.